Denali Therapeutics Inc (DNLI) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.74, surpassing Wall Street's consensus estimate of $-0.77 by $0.03. Revenue remained at $0.0B, aligning with analyst expectations.
The announcement highlights Denali's ongoing efforts in the biotechnology sector, particularly in developing therapies for neurodegenerative diseases. The company has established a portfolio of product candidates aimed at crossing the blood-brain barrier, which is crucial for treating conditions such as mucopolysaccharidosis II and other neurodegenerative disorders.
Denali will host an earnings conference call to discuss these results further and provide additional insights into its business performance. Investors may find value in reviewing the full earnings release and management commentary for a comprehensive understanding of the quarter's performance and future outlook.
With a market capitalization of $2,073.29 and a trailing twelve-month EPS of $-2.58, Denali continues to navigate a challenging landscape. Upcoming earnings are scheduled for May 3, 2026, with an estimated EPS of $-0.7985 and revenue projected at $0.0B.